Insider · CIK 0001620368
Victor Sandor
director
Files at MRUS (Merus N.V.), PRLD (Prelude Therapeutics Inc), ADCT (ADC Therapeutics SA), KYMR (Kymera Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 25, 2025 | KYMR Kymera Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 26, 2025 |
| Jun 13, 2025 | ADCT ADC Therapeutics SA | FTax withholding Common Shares | -12,600 | $3.58 | $45k | 108,286 | Jun 17, 2025 |
| Jun 12, 2025 | PRLD Prelude Therapeutics Inc | AGrant or award Director Stock Option (Right to Buy)derivative | +38,000 | $0.00 | $0 | 38,000 | Jun 13, 2025 |
| Jun 3, 2025 | ADCT ADC Therapeutics SA | AGrant or award Common Shares | +40,000 | $0.00 | $0 | 120,886 | Jun 5, 2025 |
| May 22, 2025 | MRUS Merus N.V. | AGrant or award Share Option (right to buy)derivative | +13,193 | $0.00 | $0 | 13,193 | May 27, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.